Toll-like receptor (TLR)-mediated inflammatory response could negatively affect bone metabolism. In this study, we determined how osteogenesis is regulated during inflammatory responses that are downstream of TLR signaling. Human primary osteoblasts were cultured in collagen gels. Pam3CSK4 (P3C) and Escherichia coli lipopolysaccharide (EcLPS) were used as TLR2 and TLR4 ligand respectively. Porphyromonas gingivalis LPS having TLR2 activity with either TLR4 agonism (Pg1690) or TLR4 antagonism (Pg1449) and mutant E. coli LPS (LPxE/LPxF/WSK) were used. IL-1b, SH2-containing inositol phosphatase-1 (SHIP1) that has regulatory roles in osteogenesis, alkaline phosphatase and mineralization were analyzed. 3a-Aminocholestane (3AC) was used to inhibit SHIP1. Our results suggest that osteoblasts stimulated by P3C, poorly induced IL-1b but strongly upregulated SHIP1 and enhanced osteogenic mediators. On the contrary, EcLPS significantly induced IL-1b and osteogenic mediators were not induced. While Pg1690 downmodulated osteogenic mediators, Pg1449 enhanced osteogenic responses, suggesting that TLR4 signaling annuls osteogenesis even with TLR2 activity. Interestingly, mutant E. coli LPS that induces weak inflammation upregulated osteogenesis, but SHIP1 was not induced. Moreover, inhibiting SHIP1 significantly upregulated TLR2-mediated inflammatory response and downmodulated osteogenesis. In conclusion, these results suggest that induction of weak inflammatory response through TLR2 (with SHIP1 activity) and mutant TLR4 ligands could enhance osteogenesis.
INTRODUCTION
Osteoblasts play a central role in bone remodeling by directly regulating osteogenesis and also mediate bone resorption by coordinating with bone resorbing osteoclasts. During physiologic conditions, this dynamic bone remodeling is controlled by precise orchestration of osteoblasts and osteoclasts. 1 An imbalance in this homeostasis is linked to metabolic bone diseases, such as osteoporosis and inflammatory bone diseases. 2 During chronic inflammatory conditions, such as arthritis and periodontitis, bone homeostasis is skewed towards osteoclast-induced bone resorption. 1 Toll-like receptors (TLRs) are principal pattern recognition receptors that recognize a broad category of microbial structures. TLR2 recognizes structures from Gram-positive bacteria and TLR4 receptor complex recognizes lipopolysaccharide (LPS) from Gram-negative bacteria.
3 TLR signaling can indirectly or directly affect bone homeostasis.
As an indirect mechanism, inflammatory cytokines that are downstream of TLR signaling mediate bone loss. For instance, osteoblasts also express TLRs 4 and secrete inflammatory cytokines, which in turn induce osteoclast activation. Moreover, osteogenic differentiation can be inhibited during inflammation which also contributes to inflammatory bone loss. 5 Osteoblasts, similar to macrophages, 6 downmodulate cytokine secretion during chronic TLR challenge. 7 Monocytes or macrophages, for instance, upregulate anti-inflammatory SH2-containing inositol phosphatase-1 (SHIP1) 8 and regulate inflammatory response. SHIP1 also regulates osteoblast proliferation, differentiation and survival via the PI3K/Akt signaling. 9 Currently, little is known as to how direct TLR activation in osteoblasts regulates TLR downstream events and osteogenic functions. The objectives of this study were to determine how inflammatory responses downstream of TLR2 and TLR4 signaling and SHIP1 activity regulate osteogenesis.
MATERIALS AND METHODS
Human primary osteoblast and monocyte culture Human primary osteoblasts were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA). Osteoblasts (from three different donors) were grown in a-MEM supplemented with penicillin, streptomycin and 10% heat inactivated fetal bovine serum and all reagents were purchased from Sigma-Aldrich (St Louis, MO, USA).
Osteoblasts were employed between passages of three -five and culture media was further supplemented with 100 mg?mL 21 of ascorbic acid and b-glycerophosphate (Sigma-Aldrich) to induce differentiation. Three-dimensional collagen gels with osteoblasts were cultured in cell culture wells of 12 mm diameter containing a 0.4 mm pore sized polyester membrane trans-wells (Corning Incorporated, Corning, NY, USA) as previously described. 10 Collagen gels were prepared by mixing 3 mg?mL 21 of type I rat tail collagen (Invitrogen, Carlsbad, CA, USA), a-MEM with 10% heat inactivated fetal bovine serum and osteoblast suspension (final concentration of 1.33 310 5 cells per mL). Three milliliters of gel solution was added to each transwell resulting in 4 310 5 cells per transwell. The gels were allowed to undergo initial contraction by incubating at 37 6 C for 2 h. Two milliliters of culture medium was subsequently added and the cultures were incubated at 37 6 C in a humidified atmosphere with 5% CO 2 for 7 days. Half of the media was changed and replenished every 2 days during the culture. Peripheral blood monocytes were isolated from mononuclear fraction by means of adherence and cultured in RPMI1640 as described previously. 6, 11 The percentage of viable osteoblasts or monocytes (typically .90%) was monitored by trypan blue (Invitrogen) exclusion.
TLR ligands, bacterial strains and LPS purification Pam3CSK4 (P3C) and Escherichia coli LPS (EcLPS) were employed as pure TLR2 and TLR4 ligands respectively and were obtained from Invitrogen. LPS preparations from E. coli mutant strains and from P. gingivalis were previously described [12] [13] and are summarized as follows: the E. coli msbB strain contains an inactivating mutation in the genetic locus that encodes the lipid A secondary myristoyl transferase, msbB. As a consequence, these bacteria produce penta-acylated, bis-phosphorylated lipid A lacking the secondary myristate at the 39 position of the glucosamine disaccharide backbone. Therefore, this lipid A resembles the structure of the penta-acylated lipid A. The coding sequences for Francisella novicida LpxE and LpxF lipid A phosphatases were previously cloned into the expression vector pWSK29, yielding the plpxE and plpxF constructs, respectively. To create the recombinant E. coli msbB, the vectors pWSK29, plpxE and plpxF were transformed into the E. coli msbB strain by electroporation.
The resulting recombinant strains were designated as WSK, LPxE and LPxF respectively. LPS was isolated from these E. coli mutant strains and from Porphyromonas gingivalis ATCC 33277 strain using cold MgCl 2 -C 2 H 5 OH procedure. LPS was purified by using TRI Reagent approach and crude LPS was subjected to modified Folch extraction to remove phospholipids and further treated to remove trace amounts of proteins detected by enhanced colloidal gold staining. Total fatty acid content of LPS was analyzed by gas chromatography and the purified LPS preparations were subsequently analyzed by negative ion MALDI-TOF-MS for the structural determination. Two detected ion peaks that were clustered around mass of 1 690 and 1 435/1 449 were designated as penta-acylated P. gingivalis LPS (Pg1690) and tetra-acylated P. gingivalis (Pg1449), respectively . All LPS preparations were employed at 1 mg?mL 21 (unless otherwise specified).
Cytokines, antibodies and microplate assays Recombinant TNF-a was purchased from R and D Systems (Minneapolis, MN, USA) and 1-100 ng?mL 21 of TNF-a was used in cell cultures. Anti-TLR2 (clone TL2.1) and anti-TLR4 (clone HTA125) directly conjugated (for flow cytometry) or purified (for functional blocking) antibodies were purchased from eBiosciences (San Diego, CA, USA) and were employed at a concentration of 10 mg?mL 21 . 3 a-aminocholestane (3AC), an inhibitor of SHIP1 was purchased from Echelon (Salt Lake City, UT, USA). Malachite Green assay, a fluorescent polarization assay that detects the 59-inositol phosphatase activity of SHIP1, was purchased from Echelon (Salt Lake City, UT, USA) and employed to measure SHIP1 activity.
Real-time PCR analysis
The cultures were washed twice with PBS and were incubated in 300 mL PBS containing 1 mg?mL 21 type II collagenase as previously described. 6, 11 Total RNA was extracted using QIAGEN (Germantown, MD, USA) RNeasy mini kits according to the manufacturer's instructions. Avian reverse transcriptase (RT)-PCR first-strand kits (Sigma, St Louis, MO, USA) were used to synthesize cDNA from total RNA. The concentration of total RNA was determined at 260 nm (OD 260 ) and the purity of the cDNA was determined at OD 260 /OD 280 . Nucleotide sequences were obtained from PubMed (National Center for Biomedical Information) and the primers were custom designed using primer3 software . The following primers were employed:  TLR2, 59-GGA GGC TGC ATA TTC CAA GG-39 and 59-GCC AGG CAT CCT CAC AGG-39; TLR4, 59-CTT GAC CTT  CCT GGA CCT CTC-39 and 59-ACT TGG AAA ATG CTG TAG  TTC C-39; IL-1beta, 59-GGC AGA AAG GGA ACA GAA  AGG-39 and 59-AGT GAG TAG GAG AGG TGA GAG  AGG-39; SHIP1, 59-CTG AGG CTG GAA GAA AAA CG-39 and 59-GCA CTT AGC ACA GCA CTT GG-39; beta-actin, 59-ACT CTT CCA GCC TTC CTT CC-39 and 59-GTT GGC GTA  CAG GTC TTT GC- was added and incubated for 15 min at room temperature. Calcium deposition was measured by determining the absorbance at OD 570 using a microplate reader. All analyses were performed in triplicate.
Data analysis All the experimental data were prepared and statistical analysis performed by employing Sigma Plot 11.0 software (San Jose, CA, USA). Student's t-test and one way ANOVA (all pair-wise multiple comparison procedures) were performed to determine statistical significance.
RESULTS
Osteoblasts resist upregulation of TLR2 and TLR4 in response to TLR ligands Osteoblasts express TLRs and play a role in inflammatory response by secreting cytokines. However, little is known about the constitutive expression of TLRs and how TLR expression is regulated in osteoblasts. In this study, the TLR2-but not TLR4-activated osteoblasts enhances osteogenic functions Expression of alkaline phosphatase (ALP) and in vitro mineralization are suggestive of osteogenic functions and these could be negatively regulated when osteoblasts are challenged with microbial stimuli. 16 Osteoblasts were either unstimulated or stimulated with 1 mg?mL 21 of either P3C or EcLPS and were cultured for 1 week in three-dimensional collagen gels as previously reported 10 and summarized in materials and methods.
The expression of ALP and in vitro mineralization were analyzed through histochemical ( ) for 1 week. Total RNA was extracted and quantitated and its purity confirmed as described in the section on 'Materials and methods'. cDNA was synthesized from identical quantities of toral RNA from all the samples. The purity of cDNA was determined by analysis of the OD 260 /OD 280 ratio. mRNA quantitation was performed by real-time RT-PCR analysis. Levels of b-actin mRNA served as an internal control to normalize samples. All analyses were performed in triplicate. RT-PCR was performed as described in the section on 'Materials and methods' to determine the expression of TLR2 (a, i) and TLR4 (b, j). Surface expressions of TLR2 (c-e; k-m) and TLR4 (f-h; n-p) were analyzed through flow cytometry as described in materials and methods. Isotype-matched antibody controls (Iso) are shown for TLR2 (c, k) and TLR4 (f, n) in osteoblasts and monocytes. Shown is representative data from two individual experiments. *P50.017 and **P50.004; t-test.
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to that of unstimulated control (Figure 2c and 2d) . It is known that TLR2, relative to that of TLR4 signaling, is a weak inducer of inflammation which suggests that regulatory mechanisms during inflammatory response could modulate osteogenesis. We have previously reported that SHIP1 is a negative regulator of inflammatory responses during inflammatory conditions 6 and SHIP1 has been reported to play a role in osteogenesis. 9 We therefore determined the kinetics of inflammatory cytokines such as IL-1b and SHIP1 when osteoblasts were stimulated with P3C and EcLPS (Figure 2e-2h) . The data suggests that, EcLPS significantly upregulated IL-1b (Figure 2e ), but SHIP1 was not induced (Figure 2f ). On the contrary, P3C poorly induced the expression of IL-1b (Figure 2e ), but significantly upregulated SHIP1 (Figure 2f ). Expression of SHIP1 and IL-1b bear an inverse relationship trend (although not statistically significant) when osteoblasts were stimulated with P3C ( Figure 2g ) but not with EcLPS ( Figure 2h ).
Weak TLR4 agonist and antagonist LPS structures enhance osteogenic functions Increased levels of hemin produce mutant P. gingivalis lipid A structures. 17 Of these, Pg1690 is a TLR4 agonist and Pg1449 is a TLR4 antagonist. 13 However, both these LPS preparations have residual lipopeptides with equivalent TLR2 activity. 13 Due to structural monophosphorylation and the number and length of fatty acid chains, Pg1690 and (b) biochemical method by measuring the absorbance of the p-nitrophenol product formed at OD 405 nm and by histochemical method. In vitro mineralization and calcium deposition was analyzed by histochemical method by using alizarin red staining (c) and biochemical method (d) by using color reagent (0.1% o-cresolphthalein complexone and 1% 8-hydroxyquinoline) and buffer reagent (500 mmol?L 21 2-amino-2-methyl-1-propanol, pH 10.7) and determining the absorbance at OD 570 (nm). All analyses were performed in triplicate and images were captured at 31 magnification. Kinetics of expressions of IL-1b (e) and SHIP1 (f) were quantitated through real-time RT-PCR by generating a standard curve and through normalization with bactin levels. Correlation of the expression of IL-1b and SHIP1 when stimulated with P3C (g) and EcLPS (h). The data is representative of four separate experiments. *P#0.005; t-test.
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is a weak TLR4 agonist relative to the canonical EcLPS and Pg1449 is weaker LPS relative to Pg1690 and thereby, exerts TLR4 antagonism. These LPS preparations are especially relevant as they enable us to know how TLR2 responses are regulated during TLR4 activation or TLR4 antagonism. We employed Pg1690 and Pg1449 LPS preparations to determine how weak or antagonistic TLR responses regulate osteogenesis. Relative to EcLPS (Figure 2a-2d ), Pg1690 moderately induced ALP (Figure 3a and 3b) and mineral deposition (Figure 3c and 3d) . Interestingly, Pg1449, being a TLR4 antagonist (and a TLR2 agonist) was a potent inducer of ALP (Figure 3a and 3b) and mineralization (Figure 3c and 3d) . Also, increasing concentration of Pg1449 relative to Pg1690, enhanced ALP (Figure 3a and 3b) and mineralization (Figure 3c and 3d) in a dose-dependent manner. An interesting finding is that, Pg1690, being both TLR2 and TLR4 agonist, was a poor inducer of SHIP1 (Figure 3f ), but significantly upregulated IL-1b (Figure 3e ). On the contrary, Pg1449 being a TLR2 agonist but a TLR4 antagonist, significantly upregulated . Weak TLR4 agonist and antagonist LPS structures enhance osteogenic functions. Osteoblasts cultured in three-dimensional collagen gels were either unstimulated or stimulated for one week with either Pg1690 or Pg1449 LPS at a concentration of 1 mg?mL 21 . Also, Pg1690 and Pg1449 were combined and employed at 2 : 1 and 1 : 2 ratios with the final total concentration of 1 mg?mL
21
. Regulation of ALP was determined by histochemical (a) and through biochemical (b) methods. In vitro mineralization and calcium deposition was analyzed by histochemical (c) and biochemical (d) methods. All analyses were performed in triplicate and images were captured at 31 magnification. Expressions of IL-1b (e) and SHIP1 (f) were quantitated through real-time RT-PCR by generating a standard curve and through normalization with b-actin levels. TLR2 (T2), TLR4 (T4) or isotype-matched (Iso) functional blocking antibodies were employed at a concentration of 20 mg?mL 21 to determine how IL-1b (g) and SHIP1 (h) are regulated with TLR activation. **All pair-wise multiple comparison procedures (Holm-Sidak method) with overall significance of 0.05. The differences in the mean values among all the groups were statistically significant (P,0.001) except that of unstimulated control and Pg1690; representative data from two separate experiments is presented. *All pair-wise multiple comparison procedures (Dunn's Method), P#0.006 relative to unstimulated control; . P50.004, t-test.
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SHIP1 (Figure 3f ) with poor IL-1b expression (Figure 3g ). These results suggest that TLR4 signaling could annul TLR2-induced SHIP1 and upregulate inflammatory response. TLR2 (T2), TLR4 (T4) and isotype-matched (Iso) functional blocking antibodies were employed (Figure 3g and 3h ) and the data suggest that SHIP1 expression is induced by TLR2 but not by TLR4. It should be noted that the blocking antibodies might also have some TLR activity, as stimulation with Pg1449 along with T4 did not induce SHIP1 expression (Figure 3h ). The studies with EcLPS ( Figure 2) and with LPS structures from P. gingivalis (Figure 3) suggest that the potency of TLR4 activation could be a key regulator in negatively interfering with osteogenesis.
Altering the potency of TLR4 responses enhances osteogenic functions In this study, we aimed to determine whether low doses of EcLPS have any positive influence on osteogenic functions. The data suggests that EcLPS employed at 1 ng?mL 21 moderately induced ALP (Figure 4a and 4b) Figure 4 . Altering the potency of TLR4 responses enhances osteogenic functions. Osteoblasts cultured in three-dimensional collagen gels were either unstimulated or stimulated for one week with either 1 000 ng?mL 21 P3C or 1-1 000 ng?mL 21 of EcLPS (a-j). Additionally, mutant LPS structures namely LPxF, LPxE and WSK were purified as described in materials and methods and were employed to stimulate osteoblasts at a concentration of 1 mg?mL 21 (e-j). Regulation of ALP was determined through histochemical (a, e) and biochemical (b, f) methods and regulation of in vitro mineralization/calcium deposition was analyzed by histochemical (c, g) and biochemical (d, h) methods. All analyses were performed in triplicate and images were captured at 31 magnification. Expressions of IL-1b (i) and SHIP1 (j) were quantitated through real-time RT-PCR by generating a standard curve and through normalization with b-actin levels. Expression of ALP (a, b) and mineralization (c, d) were downmodulated with EcLPS in a dosedependent manner. Relative to EcLPS, mutant LPS structures (LPxF, LPxE and WSK) were potent inducers of ALP (e, f) and in vitro mineralization (g, h). Real-time PCR data suggests that mutant LPS structures (LPxF, LPxE and WSK) were weak inducers of both IL-1b (i) and SHIP1 (j) relative to EcLPS-induced IL-1b (i) and P3C-induced SHIP1 (j). The experiments were repeated twice and representative data is shown. *P#0.001, t-test; **P#0.05, t-test.
Potency of inflammatory response and osteogenesis M Muthukuru et al 7
( Figure 4c and 4d) and this was downmodulated in a dosedependent manner. We subsequently determined how mutant LPS structures that are weak TLR4 agonists (and therefore, weak inducers of inflammatory response) regulate osteogenic mediators. Mutant EcLPS structures namely, LPxF, LPxE and WSK were used along with P3C (positive control) and canonical EcLPS (negative control). When compared with EcLPS, osteoblasts stimulated with LPxF, LPxE or WSK significantly induced the expression of ALP (Figure 4e and 4f) and upregulated in vitro mineralization (Figure 5g and 5h) . However, the induction of ALP and mineral deposition was more potent when osteoblasts were stimulated with P3C (Figure 5e and 5h). Moreover, SHIP1 was not significantly upregulated when osteoblasts were stimulated with any of the mutant LPS (i.e., LPxF, LPxE or WSK) relative to stimulating with P3C ( Figure 5j ). Despite lower induction of SHIP1, IL-1b was also not strongly induced by these mutant LPS structures relative to stimulation with the canonical EcLPS (Figure 5i ). These results suggest that, irrespective of the potency of LPS structures that target TLR4, SHIP1 expression is not under the control of TLR4 signaling. Therefore, upregulation of osteogenic mediators in response to LPxF, LPxE or WSK, could be facilitated due to a weak inflammatory response mediated by these mutant LPS structures.
Potency of the inflammatory response negatively regulates and overrules TLR2-mediated osteogenic mediators During inflammatory conditions, cytokines such as TNF-a negatively affect osteogenic functions. 18 In order to determine how osteogenesis mediated by TLR2 is affected by the potency of the inflammatory response, TNF-a was simultaneously added in doses from 0-100 ng?mL 21 to osteoblasts that were unstimulated or stimulated with either P3C or EcLPS (Figure 5a and 5d ). Relative to unstimulated controls, TNF-a at a dose of 100 ng?mL 21 downmodulated ALP expression (Figure 5a and 5b) and in vitro mineralization (Figure 5c and 5d). ALP (Figure 5a and 5b) and mineralization (Figure 5c and 5d) upregulated by P3C were inhibited by TNF-a in a dose-dependent manner. These findings suggest that osteogenic mediators induced by TLR2 signaling could be negatively affected by the potency of the inflammatory response mediated by strong TLR4 responses (Figures 2-4 ) and cytokines such as TNF-a ( Figure 5 ).
Inhibiting SHIP1 enhances TLR2-induced inflammatory response Data in Figures 2 and 3 suggest that TLR2 enhanced osteogenic mediators and levels of SHIP1. We therefore aimed to determine the role of SHIP1 in regulating osteogenesis. 3AC, an inhibitor of SHIP1, 19 was employed to determine how SHIP1 regulated IL-1b ( Figure 6 ) and osteogenic mediators (discussed in Figure 7 ). On the bases of dosedependent cytotoxicity in osteoblasts (Figure 6a ), 1-10 mmol?mL 21 3AC was employed and expression of IL-1b that was weakly induced by TLR2 was significantly upregulated when SHIP1 was inhibited by 3AC in a dose-dependent manner (data not shown). P3C and Pg1449 (TLR2 agonist but TLR4 antagonist) were employed as these ligands significantly induced SHIP1 and EcLPS was used as a negative control to determine how inhibiting SHIP1 regulates the inflammatory response. Since P3C and Pg1449 were potent inducers of SHIP1 (by activating TLR2), a significant upregulation of IL-1b was noted when 3AC was employed to inhibit SHIP1 (Figure 6b ). Since SHIP1 was not potently upregulated through TLR4 when stimulated with 
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EcLPS, IL-1b was only slightly upregulated when SHIP1 was inhibited (Figure 6b ). Malachite Green assay, a fluorescent polarization assay that detects the 59-inositol phosphatase activity of SHIP1, was employed to measure SHIP1 levels. Inhibition of SHIP1 activity with 3AC was profound when osteoblasts were stimulated with P3C or Pg1449 (Figure 6c ). . SHIP1 inhibition enhances inflammatory response in osteoblasts. Human primary osteoblasts between passages of 3-5 were cultured and incubated with 3AC at doses of 0-100 mmol?mL 21 . 3AC dose-dependent cytotoxicity in osteoblasts was determined through tryphan blue exclusion method (a). Subsequently, osteoblasts were stimulated with 1 mg?mL 21 of P3C and were incubated with varying doses of 3AC (1-10 mmol?mL
21
) and the levels of IL-1b gene expression and SHIP1 protein expression were determined and 3AC induced dose-dependent downmodulation of SHIP1 and upregulation of IL-1b (data not shown). Unstimulated osteoblasts or osteoblasts stimulated with P3C/Pg1449 alone or stimulated P3C/Pg1449 along with 10 mmol?mL SHIP1 inhibition disrupts osteoblast homeostasis Inactivating SHIP1 enhanced TLR2-induced IL-1b in a manner similar to that of TLR4 responses ( Figure 6 ). We subsequently aimed to determine how inhibiting SHIP1 regulates osteogenic mediators. Osteoblasts were stimulated with P3C, Pg1449 or EcLPS either in the presence or absence of 3AC to inhibit SHIP1. As shown in Figures 2-5 , stimulating osteoblasts with P3C or with Pg1449 significantly upregulated the expression of ALP (Figure 7a and 7c) and in vitro mineralization (Figure 7d and 7f) . EcLPS did not alter (relative to unstimulated osteoblasts) the expression of ALP (Figure 7a and 7c) and in vitro mineralization (Figure 7d and 7f). Relative to stimulation with P3C or Pg1449 alone (Figure 7a , 7c, 7d and 7f), inhibiting SHIP1 with AC3, significantly downregulated ALP expression and in vitro mineralization (Figure 7b , 7c, 7e and 7f). These data suggest that TLR2 signaling requires concurrent induction of SHIP1 for enhancing osteogenic mediators and inactivating SHIP1 made TLR2 responses similar to that of TLR4 activation.
DISCUSSION
We have presented novel findings that induction of SHIP1 in osteoblasts was under the control of TLR2 but not TLR4 signaling. Subsequently, we showed that TLR2 signaling upregulated osteogenic mediators (induction of ALP and in vitro mineralization) and these were downmodulated when SHIP1 was inhibited. We further showed that potent TLR4 activation downregulated osteogenic mediators that were induced by TLR2. These results reinforce the notion that the skeletal and immune systems share cellular receptors, cytokine networks and transcription factors. For instance, TLR signaling and inflammatory response in the innate immune system can negatively regulate bone homeostasis. However, osteoblasts also express TLRs and can directly respond to microbial stimuli 20 and secrete inflammatory cytokines such as IL-1 and TNF-a. 21 In an effort to curtail inflammatory response, studies have shown that prolonged exposure of osteoprogenitors to microbial infections resulted in downregulation of TLR expression. 22 Our data suggests that osteoblasts have low constitutive expression of TLR2 and TLR4 and are resistant to upregulation (relative to monocytes) when stimulated with TLR ligands. Low constitutive expression of TLRs has been demonstrated in mucosal 11, 23 systems. This is implicated as an adaptive measure to prevent excessive inflammatory host tissue damage. On the contrary, increased expression of TLRs has been implicated in inflammatory bowel disease. 24 The role of TLR4 in disrupting osteogenesis is supported by a study that demonstrated LPS stimulated osteoblasts resulted in reduced osteogenesis in wild-type (WT) mice, whereas osteoblasts from myd88 2/2 mice (MyD88 being an essential TLR downstream adaptor) sustained osteogenic functions. 4 In contrast, another study that employed LPS from P. gingivalis concluded that TLR2 activation resulted in poor differentiation of osteoblasts. 25 However, this study lacked evidence that the P. gingivalis LPS specifically targeted TLR2 as P. gingivalis produces heterogeneous LPS that can target both TLR2 26 and also TLR4. 27 In this study, we employed Pg1690 and Pg1449 and these LPS preparations have equivalent TLR2 activity, but Pg1690 is a TLR4 agonist and Pg1449 is a TLR4 antagonist. Osteoblasts when stimulated with Pg1690 moderately upregulated osteogenic mediators, but was not a potent inducer of IL-1b relative to EcLPS. Moreover, Pg1449 (being a weaker LPS relative to Pg1690 and also a TLR4 antagonist) significantly upregulated ALP and in vitro mineralization and IL-1b was poorly induced. These novel findings suggests that the potency of the inflammatory response mediated by TLR ligands indirectly correlated with the regulation of osteogenic functions. By employing inflammatory cytokines such as TNF-a, we demonstrated that potent inflammatory stimuli downregulate osteogenic functions that were upregulated by TLR2 responses. In mice microglial cells which are the innate immune cells of the central nervous system, TNF-a has been shown to upregulate the expression of TLR2. 28 Our data suggest that unlike monocytes, osteoblasts have low constitutive expression of TLR2 and TLR4 and these receptors are resistant to upregulation when stimulated with their ligands (Figure 1) . Further, EcLPS when employed at a 1 000-fold lower concentration moderately induced ALP and mineralization and moreover, mutant EcLPS structures induced a poor inflammatory response (relative to EcLPS) but significantly upregulated osteogenic functions. It should be noted that the composition of fatty acid chains and the number and position(s) of the phosphate groups in lipid A of LPS structure determines the TLR4 immunostimulatory potency, presumably due to their ability to engage MD2, the coreceptor of TLR4. The canonical EcLPS is hexa-acylated, 1,4-bis-phosphorylated glucosamine disaccharide and the employed mutant LPS, namely, LPxE (lipid A 19-phosphate) and LPxF (lipid A 49-phosphate) are penta-acylated monophosphorylated.
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TLR4 has a broader signaling mechanism relative to that of TLR2. TLR4 along with the Toll/interleukin receptor domain associates with a family of five adaptor proteins. 29 These adapter molecules couple with downstream protein kinases and activate transcription factors such as nuclear factor-kB and members of the interferon-regulatory factor. The adaptors can be broadly divided into MyD88-dependent (which also uses MAL or TIRAP) and MyD88-independent pathways which employ adaptors, namely, TRIF and TRAM. SRIF is the fifth adaptor which is a negative regulator of TRIF/TRAM signaling. 30 Unlike TLR4, TLR2 signaling is limited and uses only the MyD88-dependent pathways. LPS stimulated osteoblasts that were derived from Potency of inflammatory response and osteogenesis M Muthukuru et al 10 myd88
2/2 mice retained matrix mineralization and ALP activity that was comparable to unstimulated controls. 4 Also, murine osteoblasts do not have TRIF signaling 31 and these studies suggest that TLR signaling in osteoblasts only use MyD88-dependent pathway. This evidence is relevant to our current studies as SHIP1 specifically targets the MyD88 pathway. We have shown that SHIP1 is upregulated in osteoblasts in response to TLR2 but not TLR4 ligands. Moreover, inhibiting SHIP1 enhanced inflammatory response mediated by TLR2 ligands and these downmodulated osteogenic functions in a manner similar to TLR4 ligands. SHIP1
2/2 mice demonstrate increased osteoclastogenesis and bone resorption during inflammatory conditions such as arthritis. 32 Animal models that lack SHIP1 have large hyperactive osteoclasts and demonstrate severe osteoporosis. 33 Also, studies suggest that SHIP1 is essential for osteoblast development and SHIP1 2/2 mice demonstrate reduced bone growth and density. 9, 34 Induction of SHIP1 is also downstream of TGF-b signaling 8 and TGF-b has diverse cellular and anti-inflammatory functions. 35 Studies have suggested that TGF-b downmodulates IL-1R/TLR signaling and thereby suppress inflammatory response. 36 Also, evidence suggests that TGF-b-mediated anti-inflammatory effects are limited to MyD88-dependent TLR signaling 37 . This evidence makes us speculate that TLR2 responses which employ only the MyD88 pathway could be effectively antagonized by TGF-b-SHIP1 induction. On the contrary, TLR4 might require MyD88-independent pathways for inducing TGF-b and SHIP1 and at least murine osteoblast lack MyD88-independent pathways. This speculation is supported by studies that show LPS-TLR4 signaling-induced IL-1b but not TGF-b 38 and LPS hyper-responsiveness has been shown in transgenic mice that lack TGF-b signaling. 39 TLR knockout studies suggest that TLR2 but not TLR4 is associated with bone loss. For instance, peritoneal macrophages cultured with P. gingivalis differentiated into osteoclasts in response to TLR2 signaling. Moreover, culture supernatants obtained from the TLR2 2/2 macrophages induced differentiation of much fewer osteoclasts relative to supernatants obtained from WT or TLR4 2/2 macrophages. 40 These findings are supported by another study where P. gingivalis utilizes TLR2 and MyD88 in inducing osteoclast differentiation.
TLR2
2/2 mice resist alveolar bone loss relative to WT mice following oral challenge with P. gingivalis. 42 Another study presented data suggesting that WT and TLR4 2/2 but not TLR2 2/2 mice were susceptible to periodontal bone loss. 43 These studies concluded the role of TLR2 in inducing bone loss through osteoclast activation. However, these studies lack comprehensive analysis of bone loss that could be induced by disrupted osteogenesis. Figure 8 presents a schematic summary of our research findings in this study.
Osteoimmunology is an interdisciplinary field that explores the links associated with immune and skeletal systems. Newer approaches attempting to modulate immune responses 44 and bone metabolism 9, 34 by targeting SHIP1 are currently considered. Preventing osteoclast bone resorption 45 or enhancing osteogenesis through anabolic agents 46 are being explored. Therapeutic approaches that aim to enhance osteogenesis by manipulating the potency of inflammatory response would be novel. For instance, monophosphorylated LPS structures are employed as vaccine adjuncts as these altered LPS structures induce a weak inflammatory response with little host tissue damage. 47 Our studies with mutant LPS structures provide novel evidence that these molecules could enhance osteogenesis and thereby have a potential to restore bone homeostasis during inflammatory bone diseases. Potency of inflammatory response and osteogenesis M Muthukuru et al 11
